Press Release: Solana Unchained Outlines Fixed-Supply Utility Architecture and AI Tool Hub Ahead of Late May Public Allocation Launch

Choose a language:

Globe NewsWire News Distribution Service

Details: Written by Globe NewsWire Press Releases; Category: Globe NewsWire News Distribution Service; Published: 31 May 2026; Created: 31 May 2026; Last Updated: 31 May 2026

SACRAMENTO, Calif, May 30, 2026 (GLOBE NEWSWIRE) -- Solana Unchained today disclosed the comprehensive operational structure of its upcoming decentralized platform, which unifies artificial intelligence features with three specialized infrastructure protocols. Scheduled to open its initial public allocation phase on May 30, 2026, the ecosystem establishes a functional framework where every internal network service requires…

Posted: 2026-05-31 03:29:00

Get Full News Story On GlobeNewsWire Press Release Service

More News From This Category
Press Release: פרק חדש מתפתח ביחסי פקיסטן-סין
Sun, 31 May 2026 01:07:40 +0000

איסלאמאבאד, May 31, 2026 (GLOBE NEWSWIRE) -- משרד ההסברה והשידור הפקיסטני (MoIB) אחראי על קידום וניהול הנרטיב הרשמי סביב ביקורו של ראש ממשלת פקיסטן שהבז שריף בסין, בציון 75 שנה לכינון היחסים הדיפלומטיים.

Press Release: UPST DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action – UPST
Sat, 30 May 2026 22:07:39 +0000

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

Press Release: Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Sat, 30 May 2026 19:07:40 +0000

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Press Release: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Sat, 30 May 2026 16:07:39 +0000

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio –

Related Bing News Results